Genetic mutations in many forms of ALS lead to early problems with the transport and function of mitochondria, a study found.

Some patients with a rare form of ALS benefited from an experimental therapy, with biomarker evidence of reduced injury to neurons and even limited functional recovery.

Treatment with an experimental drug has shown significant improvements in young patients with a rare form of Amyotrophic ...

Data from 12 patients – all treated with a novel therapy for a rare form of ALS caused by a genetic mutation in a gene called ...

Researchers say a full-scale clinical trial of the therapy could help many patients with a particularly aggressive form of ...

An experimental drug known as ulefnersen has shown remarkable efficacy in treating a rare, aggressive form of ALS ...

Experimental drug Ulefnersen offers hope for rare, early-onset Amyotrophic lateral sclerosis (ALS) in clinical trials.

Typically, the goal of ALS treatments is to slow the disease or halt progression. But new data from the antisense oligonucleotide (ASO) jacifusen for FUS-ALS show that two patients went beyond the ...

When Columbia neurologist and scientist Neil Shneider speaks to his ALS patients who volunteer for experimental therapies, he ...

but also the community of ALS patients.” Data from 12 patients—all treated with the novel therapy for a rare form of ALS caused by a genetic mutation in a gene called FUS—were presented in a ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...